Literature DB >> 7707395

Nicotine patch use in the general population: results from the 1993 California Tobacco Survey.

J P Pierce1, E Gilpin, A J Farkas.   

Abstract

BACKGROUND: Evidence from controlled clinical trials indicates that use of a transdermal nicotine patch improves abstinence rates up to a year after initial smoking cessation. Whether these results can be generalized to the general population has not been extensively investigated.
PURPOSE: We sought to determine what characteristics of smokers trying to quit are associated with nicotine patch use in the general population and whether there is evidence that patch use promotes successful smoking cessation.
METHODS: As part of the 1993 California Tobacco Survey, 3281 respondents who had attempted to quit smoking cigarettes within the last year were asked whether they had used a prescribed medication to help them quit smoking and, if so, what type of medication it was. They were also asked whether they used other assistance.
RESULTS: Compared with nonusers, patch users (nearly 11% of quitters) were more likely to be female, white or Asian, middle-aged, and to smoke more heavily. Many people relapsed to smoking while they were still using a patch. However, no evidence suggested that the patch was addictive. Use of a nicotine patch did not result in a statistically significant difference in abstinence rates among those who did not also use some other form of assistance (logrank test, P = .466). It did make a statistically significant difference when used in combination with another aid (logrank test, P = .017). At 6 months, abstinence rates were 15% for those without other forms of assistance whether or not they used a patch, 10.9% (95% confidence interval [CI] = 5.1-16.8) for those with other assistance who did not use a patch, and 18.8% (95% CI = 5.7-31.8) for those with other assistance who did use a patch.
CONCLUSIONS: The nicotine patch appears to be an important aid to smokers who want to quit, primarily when used as an adjuvant to other forms of assistance. IMPLICATIONS: Further studies are needed to determine what factors are associated with quitting success among patch users.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707395     DOI: 10.1093/jnci/87.2.87

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  Does over-the-counter nicotine replacement therapy improve smokers' life expectancy?

Authors:  W F Lawrence; S S Smith; T B Baker; M C Fiore
Journal:  Tob Control       Date:  1998       Impact factor: 7.552

2.  Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status.

Authors:  Anne N Thorndike; Lois Biener; Nancy A Rigotti
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

3.  Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials.

Authors:  J T Hays; I T Croghan; D R Schroeder; K P Offord; R D Hurt; T D Wolter; M A Nides; M Davidson
Journal:  Am J Public Health       Date:  1999-11       Impact factor: 9.308

Review 4.  A meta-analysis of the efficacy of over-the-counter nicotine replacement.

Authors:  J R Hughes; S Shiffman; P Callas; J Zhang
Journal:  Tob Control       Date:  2003-03       Impact factor: 7.552

5.  Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers.

Authors:  S G Gourlay; A Forbes; T Marriner; D Pethica; J J McNeil
Journal:  BMJ       Date:  1995-08-05

6.  Cigarette consumption and sales of nicotine replacement products.

Authors:  T Hu; H Y Sung; T E Keeler; M Marciniak
Journal:  Tob Control       Date:  2000       Impact factor: 7.552

7.  Examining the effects of tobacco treatment policies on smoking rates and smoking related deaths using the SimSmoke computer simulation model.

Authors:  D T Levy; K Friend
Journal:  Tob Control       Date:  2002-03       Impact factor: 7.552

8.  A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.

Authors:  Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker
Journal:  Arch Gen Psychiatry       Date:  2009-11

Review 9.  Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.

Authors:  Jack E Henningfield; Saul Shiffman; Stuart G Ferguson; Ellen R Gritz
Journal:  Pharmacol Ther       Date:  2009-04-08       Impact factor: 12.310

Review 10.  Microfabrication for Drug Delivery.

Authors:  Brendan Koch; Ilaria Rubino; Fu-Shi Quan; Bongyoung Yoo; Hyo-Jick Choi
Journal:  Materials (Basel)       Date:  2016-08-01       Impact factor: 3.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.